ZINCODERM Range of Topical Creams
(Zincoderm, Zincoderm G, Zincoderm M, Zincoderm GM)
 |
The first company to introduce Topical Zinc concept
by the introduction of Zincoderm group of creams which brings in a breakthrough in dermato-therapy
| Ø |
Topical Zinc is an immuno-regulator |
| Ø |
Topical Zinc enhances the anti-inflammatory effect |
| Ø |
Topical Zinc prevents the super infection |
| Ø |
Topical Zinc reduces adverse effects of potent steroid |
| Ø |
Topical Zinc reduces the recurrence of dermatoses |
| Ø |
Topical Zinc is effective in the treatment |
| |
of varied dermatoses |
|
|
Compositions:
| Zincoderm skin cream 15g |
Clobetasol Propionate USP |
0.05 % w/w |
| Zinc Sulphate IP |
2.5 % w/w |
| Zincoderm-G skin cream 15g |
Clobetasol Propionate USP |
0.05 % w/w |
| Gentamicin(as Sulphate)IP |
0.1 % w/w |
| Zinc Sulphate IP |
2.5 % w/w |
| Zincoderm-M skin cream 15g |
Clobetasol Propionate USP |
0.05 % w/w |
| Miconazole Nitrate IP |
2 % w/w |
| Zinc Sulphate IP |
2.5 % w/w |
Zincoderm-GM skin cream 15g
|
Clobetasol Propionate USP |
0.05 % w/w |
| Gentamicin(as Sulphate)IP |
0.1 % w/w |
| Miconazole Nitrate IP |
2 % w/w |
| Zinc Sulphate IP |
2.5 % w/w |
Indications:
| Zincoderm: |
For steroid responsive dermatoses |
| Zincoderm-G: |
For steroid responsive dermatoses with bacterial infections |
| Zincoderm-M: |
For steroid responsive dermatoses with fungal infections |
| Zincoderm-GM: |
For steroid responsive dermatoses with mixed infection |
Contra-Indications:
Primary cutaneous viral infections.
Perioral dermatitis.
Hyper sensitivity to clobetasol propionate or gentamicin or miconazole nitrate or zinc sulphate preparation.
Zincoderm-G should not be used for the treatment of otitis externa.
Adverse Reactions:
Burning sensation
Dosage:
| Ø |
Apply sparingly to the affected area once or twice daily. |
| Ø |
Active topical steroid preparation therapy should be discontinued |
|
when control is achieved.Treatment should not be continued for more than two weeks. |
| Ø |
Total dosage should not exceed 50g per week without the patient condition being reviewed because of the |
|
potential for the drug to suppress the hypothalamus pitutory adrenal axis. |
Presentation:
Cream packed in 15 gm printed aluminium tube
|
